Cisplatin liposomal - ALZA

Drug Profile

Cisplatin liposomal - ALZA

Alternative Names: SPI 077; SPI 77

Latest Information Update: 16 Apr 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALZA Corporation
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 16 Apr 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (unspecified route)
  • 23 Jul 2001 A phase II study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top